Meeting
2023 ASCO Annual Meeting
PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.
Authors
Ruben Raychaudhuri
Fred Hutchinson Cancer Center, Seattle, WA
Ruben Raychaudhuri , George Mo , Michael C. Haffner , Colm Morrissey , Gavin Ha , Evan Y. Yu , Heather H. Cheng , Todd Yezefski , Jessica E. Hawley , Robert Bruce Montgomery , Peter Nelson , Delphine L. Chen , Amir Iravani , Michael Thomas Schweizer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5055)
DOI
10.1200/JCO.2023.41.16_suppl.5055
Abstract #
5055
Poster Bd #
149
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world clinical outcomes of patients treated with Lu-177-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC): A single-institution experience.
First Author: Valeria Maldonado Grijalva
Poster
2024 ASCO Genitourinary Cancers Symposium
Association of prior poly(ADP-ribose) polymerase (PARP) inhibitor therapy with response to 177Lu-PSMA-617 (LuPSMA) in men with DNA damage repair (DDR) mutations.
First Author: Ruben Raychaudhuri